Navigation Links
New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
Date:3/15/2008

d distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi- aventis' annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update o
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
2. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
3. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. PARI Nebulizer & Compressor Used Exclusively in Inspires Phase 3 CF Trial
7. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
8. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
9. Multi Merci Trial Results Published in Peer Reviewed Journal
10. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Calif. , Aug. 27, 2014  After the ... and Personal Injury billing solution for medical practices ... positive response toward the new software. "The ... Sandy Thompson . "The sheer number of demos ... true the need was for these types of software ...
(Date:8/27/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global ... participating in the Morgan Stanley 2014 Global Healthcare Conference ... New York , on Tuesday, September 9, 2014.  ... will be presenting at 9:10 a.m. Eastern Time.  ... join Mr. Dvorak for the Q&A session. ...
(Date:8/27/2014)... 2014 Sinovac Biotech Ltd. (NASDAQ: SVA ), ... , today announced the results of the Company,s 2014 Annual General ... Beijing , PRC. The required quorum, a majority of ... The Company,s shareholders approved the following proposals:  , The ... Simon Anderson , Kenneth Lee and Meng ...
Breaking Medicine Technology:Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... 2011 Ingenious Med, the leading platform for automated ... now available on the App Store for iPhone, iPod ... part of the company,s presence at the Hospital Information ... Ingenious Med,s 9,000 users to access the charge and ...
... Feb. 17, 2011 NexBio, Inc. announced the presentation ... a Patient after Allogeneic Stem Cell Transplantation" at the ... February 17-21 in Honolulu, Hawaii.  The data was presented ... General Hospital and Harvard Medical School. Parainfluenza ...
Cached Medicine Technology:HIMSS11: Ingenious Med Launches Billing and Data Capture App for iPhone, iPod touch and iPad 2NexBio’s DAS181 (Fludase®*) Improved Symptoms in a Severely Immunocompromised Patient with Parainfluenza Pneumonitis 2NexBio’s DAS181 (Fludase®*) Improved Symptoms in a Severely Immunocompromised Patient with Parainfluenza Pneumonitis 3
(Date:8/27/2014)... Aspirus Wausau Hospital today announced the first ... Digital O.R. at Aspirus Wausau Hospital, in Wausau, WI. ... rooms will be Buzz, a centralized surgical hub for ... planning, navigation, imaging and communications connectivity. , Buzz ... and hardware all controlled from the full HD 42” ...
(Date:8/27/2014)... UNIWIGS, one of the leading purveyors of real and synthetic ... sales on all its products, for the coming Labor Day. , ... UniWigs hair products in two ways: when they spend ... a coupon code LABOR10; while when they spend more than $299, ... deal which coupon code is needed when securely checkout, there are ...
(Date:8/27/2014)... Hepatocellular carcinoma (HCC) is the second leading cause ... are due to the difficulty in treating this ... epirubicin, cisplatin, 5-fluorouracil, etoposide or combinations therein. This ... are not able to reach in a sufficient ... that are not harmful to the rest of ...
(Date:8/27/2014)... Fluorochemicals are synthetically produced chemicals, which repel water ... and chemical conditions in industrial processing. These characteristics ... and products, such as coatings for food paper ... that they are difficult to break down and ... fluorochemicals have known correlations with harmful health effects, ...
(Date:8/27/2014)... 27, 2014 DISCcert has scheduled its ... place Sept 10th, 17th, 24th, and Oct 1st from ... receive a certification seal that will allow them to ... consists of four weekly one-hour webinar sessions. In between ... are offered individual coaching time. , Trainers, participating ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 2Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 3Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 3Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 2Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 3Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 4
... researcher Dr. Daniel Von Hoff, a member of ... in-depth look at the "lost opportunity" in phase ... companies use the phase I trial to evaluate ... advocates that it can also provide valuable efficacy ...
... have made several, subtle changes in the structure of a ... according to a study published in a December edition of ... have profound implications for the treatment of hemophilia, the inherited ... Americans. , In most cases, hemophilia is ...
... those with lupus, rheumatoid arthritis , , MONDAY, Dec. 22 ... cells, but these cells stay in an "off" state, ... the body cause autoimmune diseases such as lupus and ... adults are true precursors of the self-attacking immune cells ...
... common this time of year , , MONDAY, Dec. 22 ... holidays this year, with many people both blue and ... jobless rate in three decades and a jackknifing stock market. ... often during the winter months not only because of the ...
... fresh start for career-building in today,s tough economic times. The ... professions. , ... (PRWEB) December 22, ... a recruiting campaign targeting career changers and other potential students. ...
... 2008, Cambridge, UK Scientists report that human gene mutations ... Disease, a fatal nervous system disorder that begins during childhood. ... (DMM), dmm.biologists.org , describes how the extent of ... in humans. ,The initial, milder symptoms of Batten ...
Cached Medicine News:Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 2Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 3Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 4Health News:Redesigned protein accelerates blood clotting 2Health News:Redesigned protein accelerates blood clotting 3Health News:Redesigned protein accelerates blood clotting 4Health News:Blue and Broke for the Holidays 2Health News:Blue and Broke for the Holidays 3Health News:Blue and Broke for the Holidays 4Health News:Parker College of Chiropractic Education Launches Recruiting Campaign for Career Changers and Potential Students 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: